PHYOXTM Clinical Trial Program
The Company’s lead GalXCTM product candidate, DCR-PHXC, now referred to as nedosiran, is in clinical development for the treatment of Primary Hyperoxaluria (PH). The PHYOX2 clinical trial is enrolling patients with PH type 1 (PH1) and PH type 2 (PH2). For more information about the PHYOXTM clinical trial program or to find the clinical trial sites, please contact Dicerna at email@example.com or go to https://www.clinicaltrials.gov/ct2/show/NCT03847909.
Please note, depending on a person’s eligibility to participate in the clinical trial, expenses to travel to a clinical trial site will be covered by Dicerna.
Participating in a Trial
Physicians at leading research institutions who specialize in the treatment of PH are conducting the PHYOXTM clinical trials. If you or a loved one has been diagnosed with PH and would like to participate in a clinical trial, please submit your information through the form below:
For more information on the trial, please view the Frequently Asked Questions page, visit clinicaltrials.gov and enter the identifier number NCT03847909 or click on the following link: https://www.clinicaltrials.gov/ct2/show/NCT03847909.